Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Fiche publication
Date publication
mai 2023
Journal
Neurology(R) neuroimmunology & neuroinflammation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D
Lien Pubmed
Résumé
Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms of action of OCR and on the disease pathophysiology.
Mots clés
Humans, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Multiple Sclerosis, drug therapy, Leukocytes, Mononuclear, Antibodies, Monoclonal, Humanized, therapeutic use
Référence
Neurol Neuroimmunol Neuroinflamm. 2023 05;10(3):